Diagnostics

With the hire of a top scientist, a minority-owned IT firm signals its ambition to tackle complex federal health challenges and compete with industry giants.

Treating over 100,000 patients in two years, a novel gel therapy is leading a paradigm shift in interventional dry eye management. Here's how.

Karl Blackburn, former head of Quebec’s top employers’ council, takes the helm at the Montreal Heart Institute Foundation, signaling a new era.

A new paper warns that Lyme disease may pass from mother to child, a risk overlooked for decades. Researchers are now demanding urgent action and funding.

The deal merges a leading health data platform with mobile diagnostics, aiming to remove barriers to proactive wellness and deliver lab tests anywhere.

As Spectral AI preps its revolutionary DeepView wound scanner for launch, new CFO David McGuire brings crucial public company expertise to a pivotal transition.

Amid industry-wide financial strain, Kurin's simple device for preventing blood culture contamination delivers record growth by saving hospitals money and lives.

Former Biosynth CEO Dr. Urs Spitz joins Ribbon Bio, signaling a major push to commercialize its groundbreaking cell-free DNA synthesis platform.

A new certification for AI-guided cardiac ultrasound seeks to solve the training and trust gap, making crucial heart scans more accessible for frontline providers.

Miami startup Petwealth emerges from stealth with at-home PCR tests and key partnerships, aiming to revolutionize the $200B pet health industry.

As lung cancer becomes a growing crisis for women, the LCRF gala honors two leaders driving change and rallying support for life-saving research.

A new partnership brings a groundbreaking protocol for corneal blindness to Chicago, expanding a national network dedicated to restoring vision for thousands.

Language services leader GLOBO hires a new CTO with deep AI expertise, signaling a major push to revolutionize communication for underserved populations.

AIRNA has dosed the first patient with AIR-001, an RNA-editing drug that could treat both the lung and liver damage of a devastating genetic disease.

A new AI software that analyzes MRI scans has received a first-of-its-kind FDA classification, promising to help doctors differentiate complex brain disorders.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

Boston's Bio-IT World conference shifts from AI theory to execution, showcasing how the life sciences industry is now deploying AI to accelerate new therapies.

This April, families nationwide are walking to fund a new strategy for Lennox-Gastaut Syndrome, aiming to slash diagnosis times and find real cures.

As 'forever chemicals' plague South Florida, a new, costly plasma exchange therapy offers a solution. But is it a medical breakthrough or a luxury trend?

Biopharma firm GENFIT sees soaring Iqirvo sales and a cash runway past 2028, overshadowing a net loss driven by strategic, non-cash write-downs.